ReviewDrugs2007
The clinical applications of fluorouracil in ophthalmic practice.
Review in Drugs, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 89 citations in OpenAlex.
- Topical pharmacotherapy for ocular surface squamous neoplasia: systematic review and meta-analysis.Scientific reports · 2022Pooled it
- Topical fluorouracil after surgery for ocular surface squamous neoplasia in Kenya: a randomised, double-blind, placebo-controlled trial.The Lancet. Global health · 2016Trial
- 5-Fluorouracil versus mitomycin C as adjuncts to conjunctival autograft in preventing pterygium recurrence.International ophthalmology · 2012Trial
- Article
- Efficacy of topical 5-Fluorouracil in the management of ocular surface squamous neoplasia: a study of 101 eyes.International ophthalmology · 2024Article
- Synergistic Therapy for Graves' Ophthalmopathy-Associated Eyelid Retraction: Steroid, 5-FU, and Botulinum Neurotoxin a Combination.Journal of clinical medicine · 2024Article
- 5-Fluorouracil as a targeted lacrimal gland therapy for chronic Stevens-Johnson syndrome: A pilot study.Indian journal of ophthalmology · 2023Article
- Mesoporous Silica Nanoparticles Coated with Carboxymethyl Chitosan for 5-Fluorouracil Ocular Delivery: Characterization, In Vitro and In Vivo Studies.Molecules (Basel, Switzerland) · 2023Article
- The Management of Ocular Surface Squamous Neoplasia (OSSN).International journal of molecular sciences · 2022Review
- Ocular surface squamous neoplasia: management and outcomes.Eye (London, England) · 2021Review
- Iatrogenic Ocular Surface Diseases Occurring during and/or after Different Treatments for Ocular Tumours.Cancers · 2021Review
- Results of fluorouracil-augmented Xen45 implantation in primary open-angle and pseudoexfoliation glaucoma.International ophthalmology · 2021Article
- Management of ocular surface squamous neoplasia: Bowman Club Lecture 2021.BMJ open ophthalmology · 2021Review
- Study of Dosage-Dependent Effects of Cytostatic Drugs Using a Fibroblast Cell Culture of the Human Nasal Mucosa.International archives of otorhinolaryngology · 2020Article
- Management Issues in Conjunctival Tumours: Ocular Surface Squamous Neoplasia.Ophthalmology and therapy · 2020Article
- Efficacy of postoperative management with 5-fluorouracil injections after XEN Gel Stent implantation.International ophthalmology · 2020Article
- Comparison of Topical 5-Fluorouracil and Interferon Alfa-2b as Primary Treatment Modalities for Ocular Surface Squamous Neoplasia.American journal of ophthalmology · 2019Article
- Update on Diagnosis and Management of Conjunctival Papilloma.Eye and vision (London, England) · 2019Review
- Update on pharmacotherapy for ocular surface squamous neoplasia.Eye and vision (London, England) · 2019Review
- Reduced intraepithelial corneal nerve density and sensitivity accompany desiccating stress and aging in C57BL/6 mice.Experimental eye research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fluorouracil (5-fluorouracil, 5-FU) is a pyrimidine analogue that was originally known for its widespread use as an anticancer drug. The ability of 5-FU to reduce fibroblastic proliferation and subsequent scarring has made it an important adjunct in ocular and periorbital surgeries. It is used in primary glaucoma filtering surgeries and in reviving failing filtering blebs, in dacryocystorhinostomy, pterygium surgery, and in vitreoretinal surgery to prevent proliferative vitreoretinopathy. In addition, 5-FU is also gaining recognition in the treatment and surgical management of ocular surface malignancies like ocular surface squamous neoplasia; however, the specific action of the drug on highly proliferating cells limits its use in primary acquired melanosis of the conjunctiva. When applied topically, this drug has a low rate of sight-threatening adverse effects, is inexpensive, and is easy to administer, making it an important tool in enhancing the success rate in ophthalmic surgery and in reducing the recurrence of ocular surface neoplasia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.